These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22499047)

  • 1. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
    Tomonaga M; Kamae I
    Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
    Gidwani R; Khan ZM; Fenaux P; Beach CL; Pashos CL
    J Med Econ; 2012; 15(1):145-54. PubMed ID: 21988635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and cost-effectiveness of at home azacitidine administration.
    Sampol A; Delgado E; López B
    Med Clin (Barc); 2017 Sep; 149(5):224-225. PubMed ID: 28610766
    [No Abstract]   [Full Text] [Related]  

  • 6. Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromes.
    Guirguis HR; Charbonneau LF; Tyono I; Wells RA; Cheung MC; Buckstein R
    Leuk Lymphoma; 2015 Feb; 56(2):542-4. PubMed ID: 24882261
    [No Abstract]   [Full Text] [Related]  

  • 7. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
    Fenaux P; Ades L
    Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.
    Cogle CR; Ortendahl JD; Bentley TG; Anene AM; Megaffin S; McKearn TJ; Petrone ME; Mukherjee S
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):275-84. PubMed ID: 26589773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
    Musto P; Maurillo L; Spagnoli A; Gozzini A; Rivellini F; Lunghi M; Villani O; Aloe-Spiriti MA; Venditti A; Santini V;
    Cancer; 2010 Mar; 116(6):1485-94. PubMed ID: 20151429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine in lower-risk myelodysplastic syndromes.
    Santini V
    Leuk Res; 2009 Dec; 33 Suppl 2():S22-6. PubMed ID: 20004794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
    Fenaux P; Bowen D; Gattermann N; Hellström-Lindberg E; Hofmann WK; Pfeilstöcker M; Sanz G; Santini V
    Leuk Res; 2010 Nov; 34(11):1410-6. PubMed ID: 20609474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
    Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
    Santini V
    Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
    Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
    Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
    Demakos EP; Linebaugh JA
    Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacoeconomic evaluation of combination therapy with dutasteride and α1 blocker for treatment of benign prostatic hyperplasia in Japan].
    Takayama T; Arakawa I; Kakihara H; Tachibana K; Ozono S
    Hinyokika Kiyo; 2012 Feb; 58(2):61-9. PubMed ID: 22450830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes: health care management considerations.
    Kogan AJ; Dunn JD
    Manag Care; 2009 Nov; 18(11 Suppl 9):25-8; discussion 28-9. PubMed ID: 20085114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.